Neuren Pharmaceuticals Quote - NEU

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

12.46

Bid

12.43

Offer

12.64

Volume

1,148,617

12.42 Day's Range 13.68

12.02 52 Week Range 170.09

Market Cap

1.591B

Previous Close

13.66

Open

13.58

Last Trade

784

12.43

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

534,604

Shares Outstanding

127,695,676

Dividend Yield

PE Ratio

10.13

Earnings Per Share (EPS)

1.23

Revenue

231.94M

Net Profit

157.08M

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.neurenpharma.com

Headquarters

Auckland, Nzl

Founded

Neuren Pharmaceuticals Limited is listed in the Pharmaceutical Preparations sector of the Australian Stock Exchange with ticker NEU. The last closing price for Neuren Pharmaceuticals was AUD13.66. Over the last year, Neuren Pharmaceuticals shares have traded in a share price range of AUD 12.02 to AUD 170.09.

Neuren Pharmaceuticals currently has 127,695,676 shares in issue. The market capitalisation of Neuren Pharmaceuticals is AUD1.74 billion. Neuren Pharmaceuticals has a price to earnings ratio (PE ratio) of 10.13.

ACADIA Pharmaceuticals & Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment...

With No Approved Treatments in Rett Syndrome, FDA Decision Highlights Significant Unmet Need ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) and Neuren Pharmaceuticals Limited (ASX: NEU) announced...

FDA Grants Orphan Drug Designation for Neuren's NNZ-2591 to Treat Angelman, Phelan-McDermid and Pitt Hopkins Syndromes

Neuren Pharmaceuticals (ASX: NEU) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Neuren’s NNZ-2591 for the treatment of Angelman syndrome...

Positive Phase 2 Study Results of Trofinetide in Pediatric Rett Syndrome Published in Neurology, the Medical Journal of the A...

-- Statistically Significant Improvement Indicates Trofinetide’s Potential for Treating Rett Syndrome-- Trofinetide for Rett Syndrome has Fast Track Status and Orphan Drug Designation in...

ACADIA Pharmaceuticals & Neuren Pharmaceuticals Announce Exclusive License Agreement for the North American Development & Com...

-ACADIA plans to initiate a Phase 3 study of trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental congenital CNS disorder, in the second half of 2019 -Neuren...

American Stock Exchange to Trade Options on Five New Securities

NEW YORK, April 12 /PRNewswire/ -- The American Stock Exchange(R) (Amex(R)) will launch trading in options on Thursday, April 13, 2006 on the following Nasdaq Stock Market and New York Stock...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-4.48	-26.4462809917	16.94	17.94	12.42	705459	16.34906129	DE
4	-0.09	-0.717131474104	12.55	17.94	12.02	586738	14.87876625	DE
12	-3.42	-21.5365239295	15.88	17.94	12.02	534604	14.27827956	DE
26	-8.64	-40.9478672986	21.1	170.09	12.02	505033	16.67317443	DE
52	-3.04	-19.6129032258	15.5	170.09	12.02	502957	18.48163971	DE
156	10.575	561.00795756	1.885	170.09	1.685	469034	12.45686741	DE
260	9.95	396.414342629	2.51	170.09	0.965	331516	10.79624732	DE

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
HIQOHitIQ Limited	AUD 0.022 (633.33%)	25k
ARDOArgent Minerals Ltd	AUD 0.003 (200.00%)	18.41M
IFGInFocus Group Holdings Ltd	AUD 0.038 (153.33%)	61.11M
ADNOCAndromeda Metals Limited	AUD 0.002 (100.00%)	5M
FNRFar Northern Resources Ltd	AUD 0.18 (71.43%)	142.69k
OECROrbital Corporation Limited	AUD 0.001 (-98.48%)	9
ADXOADX Energy Limited	AUD 0.011 (-63.33%)	875k
CDECodeifai Ltd	AUD 0.001 (-50.00%)	82.68M
CRIOCritica Ltd	AUD 0.001 (-50.00%)	5M
AGEOCAlligator Energy Limited	AUD 0.01 (-28.57%)	36k
SYASayona Mining Limited	AUD 0.034 (-10.53%)	96.47M
CDECodeifai Ltd	AUD 0.001 (-50.00%)	82.68M
88E88 Energy Limited	AUD 0.002 (33.33%)	79.47M
PENPeninsula Energy Ltd	AUD 0.0545 (-3.54%)	72.33M
LPDLepidico Ltd	AUD 0.002 (0.00%)	65.86M